ArticleJournal of human hypertension2026
Mortality trends and demographics due to hypertensive nephrosclerosis in older adults from 1999-2020.
Article in Journal of human hypertension, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertensive Nephrosclerosis (HSN), a progressive kidney disease, has significantly impacted mortality and morbidity, via cardiovascular events, end-stage renal disease, and infections. Despite its clinical and public health impact, comprehensive analyses of U.S. mortality trends remain understudied. We aim to assess trends in Nephrosclerosis-related deaths in the United States (1999-2020). We extracted HSN-related deaths in older adults aged ≥65 years (1999-2020) using the CDC WONDER database [using ICD-10 code: I-12 (Hypertensive renal disease)]. Crude- and age-adjusted mortality rates (CMR and AAMR) per 100,000 population were determined. We used Joinpoint regression to examine changes in trends and average- and annual percentage change (AAPC and APC) overall and then stratified into demographic and geographical subgroups. A total of 519,817 deaths were recorded due to HSN. Overall, the AAMR rose from 21.51 (1999) to 132.03 (2020) [AAPC, 8.80 (95% CI: 6.53 to 12.08)], especially in age-group 85+ (CMR: 203.36). The overall mortality surged the most remarkably between 2011 and 2014 [APC, 34.74 (95% CI: 1.31 to 50.76)]. Males demonstrated higher AAMRs (67.56) than females (48.93). Racially/ethnically, Non-Hispanic (NH) Blacks (117.99), followed by Hispanics (70.22), exhibited increased vulnerability. Geographically, the Western region (65.71) and rural areas (56.88) held the highest mortality burden. State-wise AAMRs ranged between Connecticut to the District of Columbia (28.58 and 85.8, respectively). In conclusion, HSN-related mortality has increased trends over the last two decades. Males, NH Blacks, 85+ age group, individuals from Western region, and rural residents were the high-risk subgroups. These results call for future research to explore the correlation between observed disparities.
Indexed as
Identifiers
42436352What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.